Moreover, the negative regulation of FGFR, the SPRY regulation of FGF, and the positive regulation of noncanonical WNT and PI3K/AKT/IKK signaling pathways may be the key pathways regulated by DNAH10 mutation for promoting cisplatin resistance in SCLC. Here, DNAH10 is linked to small cell lung carcinoma.